XILIO THERAPEUTICS, INC.

Analyst Reco. Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
1.04 ^USD	0.00%		-0.95%	+89.09%

Apr. 19	Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	MT
Apr. 01	Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating	23-01-27	MT
Chardan Initiates Xilio Therapeutics With Buy Rating, $7 Price Target	22-12-21	MT
Raymond James Adjusts Price Target on Xilio Therapeutics to $13 From $31, Maintains Outperform Rating	22-11-10	MT
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $20 From $32, Reiterates Overweight Rating	22-08-10	MT
HC Wainwright Starts Xilio Therapeutics at Buy with $36 Price Target	22-01-10	MT
Guggenheim Starts Xilio Therapeutics at Buy With $40 Price Target	21-11-16	MT
Morgan Stanley Starts Xilio Therapeutics at Overweight With $32 Price Target	21-11-16	MT
Raymond James Starts Xilio Therapeutics at Outperform With $31 Price Target	21-11-16	MT
Cowen Starts Xilio Therapeutics at Outperform	21-11-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer